| By The Hamner Institute |
| Monday, 25 May 2009 |
 |
The Hamner Institutes for Health Sciences has signed an agreement with China Medical City to create the Hamner-China Medical City Institute for International Drug Development. Building on strengths of the two organizations in translational
|
|
research, business development, and education, the Institute will help to produce new biomedical technologies that benefit the United States and People's Republic of China as well as the rest of the world. During the first phase of this agreement, the Institute for International Drug Development will be established at The Hamner's campus in Research Triangle Park (RTP), North Carolina, and will focus on preclinical drug development and compliance with FDA regulatory standards.
After the partners validate research capabilities and new technologies at The Hamner campus, they will transfer them to China Medical City, a new life science park located in the Yangtze River Delta north of Shanghai.
In 2008, The Hamner launched a Bioscience Accelerator on its 56-acre campus in the heart of RTP. There are two initial start-ups: BioMedomics, a diagnostics company started by Chinese-American scientists, and b3bio, a spinout from Duke University.
Newsummit Biopharma, one of China Medical City's premier partners, is establishing its North American business center in The Hamner's Bioscience Accelerator. Newsummit Biopharma is a contract research and technology development company |
|
|
whose service platform includes support for commercialization, intellectual property, funding, and staffing in science and technology parks throughout China.
The partnership with China Medical City and Newsummit Biopharma creates a vital bridge of opportunity between North Carolina and China. Acknowledged worldwide as a major hub of biotechnology,North Carolina
is an ideal location for companies from China that seek to enter the U.S. market. After establishing an initial presence in RTP, which already has a strong Chinese community of scientists and business professionals, companies from China can expand around the state of North Carolina as their businesses prosper and grow.
As part of its new strategic agreement with China Medical City, The Hamner has worked with the North Carolina Department of Commerce and North Carolina Biotechnology Center, a world leader in bioscience development, to create a "North Carolina-China partner network" that supports Chinese business and educational initiatives. Other members of this innovative network include the North Carolina China Center, the North Carolina China Business Association, Council for Entrepreneurial Development, and North Carolina Research Parks Network as well as economic development organizations in counties such as Wake and Durham.
China Medical City and Newsummit Biopharma are actively using their network to assist North Carolina's R&D companies, contract organizations (research, manufacturing, and commercial), and academic institutions that want to |
|
establish strategic alliances, research sites, branch offices, etc. in China. The new Hamner Bioscience Center in China
Medical City and the North Carolina Department of Commerce office in Shanghai are serving as gateways for North Carolina
organizations, such as Cirrus, Specialty Operations Solutions, Inc., and SyneCor, that are developing new markets in China.
About the Hamner Institutes for Health Sciences
The Hamner Institutes for Health Sciences is a nonprofit research organization strategically located in
Research Triangle Park, North Carolina. The Hamner has a strong heritage in scientific scholarship and translational research. For 35 years, scientists at The Hamner have conducted small-molecule chemical safety studies to protect the environment. The Hamner has recently expanded its mission to include drug safety, NIH-funded human disease research, and support for life science start-ups. As a neutral, independent research institute, The Hamner works collaboratively with academia, government regulatory agencies, and commercial companies to accelerate the development of new bioscience technologies.
Want to read more?
Frost & Sullivan Looks At The Influence Of China's New Health Reform On The Pharmaceutical Market
Biomedical Sciences Companies Expanding In Asia
Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results |
|
|
